On the other hand, the effect of cetuximab administration in CRC patients might result in a lower therapeutic effect on the primary tumor due to the presence in situ, as we have shown by immunochemistry, of TAF that express EGFR and can subtract the antibody, thus reducing its availability (44–46). Here, EGFR is linked to neoplasm.